BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

NextCure faces a precarious outlook as it continues to operate without revenue, leading to a rapid erosion of its asset base from $128.0 million in 2023Q4 to $38.0 million in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 10, 2026 | -$1.29-43.3% vs -$0.90 | — vs — |
Q3 2026 Aug 6, 2026 | -$2.80-43.6% vs -$1.95 | — vs — |
Q2 2026 May 7, 2026 | -$1.87-3.3% vs -$1.81 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.81+64.2% vs -$2.26 | — vs — |
BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

NextCure, Inc. (NASDAQ: NXTC - Get Free Report)'s stock price was up 7.7% during trading on Tuesday. The company traded as high as $8.64 and last traded at $8.42. 95,035 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 147,812 shares. The stock had previously closed at $7.82.
Benchmark NXTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for NextCure, Inc. (NXTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.89 | $24.87M | -0.89 | — | — | -206.63% | — | |
| $1.05 | $122.39M | -1.04 | -51.24% | -2619.64% | -73.92% | — | |
| $15.76 | $1.98B | -4.51 | -4.26% | -445% | -90.04% | — | |
| $6.40 | $266.51M | 18.97 | 10.37% | 20.98% | — | — | |
| $33.17 | $6.85B | -13.47 | — | -7173.52% | -63.01% | — | |
| $66.12 | $10.12B | 97.21 | 87.32% | 11.81% | 17.62% | — |
NextCure, Inc. (NXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
NextCure, Inc. (NXTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 10, 2026·SEC
Oct 30, 2026·SEC
Aug 6, 2026·SEC
Get notified when NXTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NextCure, Inc. (NXTC) stock FAQ — growth, dividends, profitability & financials explained
No. NextCure, Inc. (NXTC) reported a net loss of $41.0M over the trailing twelve months.
NextCure, Inc. (NXTC) had a return on equity (ROE) of -206.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
NextCure, Inc. (NXTC) had negative free cash flow of $42.8M over the trailing twelve months.